TCGA-OL-A5RX-01A-11R-A28M-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 29
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.410
- MYOGENESIS+0.300
- APICAL_JUNCTION+0.290
- WNT_BETA_CATENIN_SIGNALING+0.280
- ESTROGEN_RESPONSE_EARLY+0.190
- APICAL_SURFACE+0.170
- NOTCH_SIGNALING+0.160
- UV_RESPONSE_DN+0.160
- COAGULATION+0.130
- APOPTOSIS+0.100
Top 10 suppressed
- E2F_TARGETS-0.660
- G2M_CHECKPOINT-0.590
- MTORC1_SIGNALING-0.480
- PROTEIN_SECRETION-0.440
- INTERFERON_ALPHA_RESPONSE-0.420
- MYC_TARGETS_V2-0.380
- MYC_TARGETS_V1-0.370
- GLYCOLYSIS-0.330
- UNFOLDED_PROTEIN_RESPONSE-0.330
- INTERFERON_GAMMA_RESPONSE-0.310
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-A2-A4RY-01A-31R-A266-07 | — | A | 0.896 |
| 2 | TCGA-D8-A4Z1-01A-21R-A266-07 | — | A | 0.890 |
| 3 | TCGA-A7-A4SC-01A-12R-A266-07 | — | A | 0.868 |
| 4 | TCGA-BH-A42V-01A-11R-A24H-07 | — | A | 0.861 |
| 5 | TCGA-AC-A3W7-01A-11R-A22K-07 | — | A | 0.859 |
| 6 | TCGA-BH-A28O-01A-11R-A22K-07 | — | A | 0.855 |
| 7 | X9cad7a78.ea9b.47b0.9d06.e5e696031cc3 | — | cohortA1 | 0.851 |
| 8 | SRR1313116 | — | A | 0.846 |
| 9 | BSR_05_0025_A4_S57 | — | A | 0.841 |
| 10 | TCGA-A7-A426-01A-22R-A24H-07 | — | A | 0.837 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.410 | Inavolisib | — uncovered |
| MYOGENESIS | 0.300 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.290 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.280 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.190 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.170 | Temsirolimus | — uncovered |
| NOTCH_SIGNALING | 0.160 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.160 | Inavolisib | — uncovered |
| COAGULATION | 0.130 | Binimetinib | — uncovered |
| APOPTOSIS | 0.100 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.100 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.100 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.100 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.060 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.050 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.050 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.020 | Inavolisib | — uncovered |
| HYPOXIA | 0.020 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.010 | Inavolisib | — uncovered |